Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 122

Sort by

Sort Order Select

Journal Articles

Evidence of Defective Cell-Autonomous Signalling By B Cell Receptors in CLL Stereotyped Subset #1

Claudia Minici, Paolo G. Cocomazzi, Can Akpınaroğlu, Anastasia Iatrou, Maria Gounari, Michela Frenquelli, Lydia Scarfo, Christian Buske, Andreas Agathangelidis, Hassan Jumaa, Palash Maity, Paolo Ghia, Kostas Stamatopoulos, Massimo Degano

Blood (2023) 142 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2023-181702

Published: 2023

Journal Articles

Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)

Catherine Thieblemont, Annarita Conconi, Christian Buske, Stefano Luminari, Martin Dreyling, Maria Gomes da Silva, Marc Andre, Maria Flores, Karima Brahami-Aissou, Pascale Cony-Makhoul, Sylvain Carras

Blood (2023) 142 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2023-180473

Published: 2023

Journal Articles

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

Blood (2023) 142 (Supplement 1): 6248.

https://doi.org/10.1182/blood-2023-179200

Published: 2023

Journal Articles

A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML

Blood (2023) 142 (1): 90–105.

https://doi.org/10.1182/blood.2022018651

Published: 2023

Includes: Supplemental data

Journal Articles

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Blood (2022) 140 (Supplement 1): 5285–5287.

https://doi.org/10.1182/blood-2022-157549

Published: 2022

Journal Articles

Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

Blood (2022) 140 (Supplement 1): 8729–8730.

https://doi.org/10.1182/blood-2022-162224

Published: 2022

Journal Articles

Age-Related Changes in Human HSC Methylomes Affect Gene Regulatory Elements Critical to HSC Function and Reveal Novel HSC Aging Candidate Genes

Abdul-Habib Rahimi, Reka Toth, Dieter Weichenhan, Julia K. Herzig, Ekaterina Panina, Michael Heuser, Maximilian Schönung, Daniel B. Lipka, Pavlo Lutsik, Christoph Plass, Christian Buske

Blood (2021) 138 (Supplement 1): 2166.

https://doi.org/10.1182/blood-2021-148293

Published: 2021

Journal Articles

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Steven P. Treon, Christian Buske, Sheeba K Thomas, Jorge J. Castillo, Andrew R. Branagan, Meletios A. Dimopoulos, Maria Gavriatopoulou, Diego Cadavid, Felix T Garzon, Weihua Tang, Sean Seyffert, Varun Garg, Shariq Ali, Arthur G. Taveras, Kelly Chen, Jeffrey V. Matous

Blood (2021) 138 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2021-144706

Published: 2021

Journal Articles

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-140933

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-135999

Published: 2020

Journal Articles

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Judith Trotman, FRACP, Christian Buske, MD, Alessandra Tedeschi, MD, Jeffrey V. Matous, MD, David MacDonald, MD, Constantine Tam, MBBS, Olivier Tournilhac, MD PhD, Shuo Ma, MD PhD, Steven P. Treon, MD PhD, Albert Oriol, Jerry Ping, PhD, Eva M. Briso, PhD, Israel Arango-Hisijara, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-133916

Published: 2020

Journal Articles

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Panayiotis Panayiotidis, MD, Gayane Tumyan, Catherine Thieblemont, Vadim V Ptushkin, Ana Marin Niebla, Ramon Garcia-Sanz, Andrey Zaritskey, Steven Le Gouill, MD PhD, Christian Buske, MD, Marlies Van Hoef, Thomas Perretti, Monique S Tomiczek, Anastasios Stathis, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137087

Published: 2020

Journal Articles

CXCR4 Signaling in AML Is Dampened By the Endogenous CXCR4 Inhibitory Peptide EPI-X4

Lisa Marie Kaiser, Mirja Harms, Jan Münch, Christian Buske, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-142619

Published: 2020

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum

Blood (2019) 134 (Supplement_1): 4078.

https://doi.org/10.1182/blood-2019-124297

Published: 2019

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Jorge J. Castillo, Gilad Itchaki, Jonas Paludo, Marzia Varettoni, Christian Buske, Toby A. Eyre, Julio C. Chavez, Kenneth H. Shain, Samar Issa, M. Lia Palomba, Oren Pasvolsky, David Simpson, Dipti Talaulikar, Constantine S. Tam, Alessandra Tedeschi, Stephen M. Ansell, Lakshmi Nayak, Steven P. Treon

Blood (2019) 133 (4): 299–305.

https://doi.org/10.1182/blood-2018-10-879593

Published: 2019

NARROW

Evidence of Defective Cell-Autonomous Signalling By B Cell Receptors in CLL Stereotyped Subset #1

Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)

A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML

Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

Age-Related Changes in Human HSC Methylomes Affect Gene Regulatory Elements Critical to HSC Function and Reveal Novel HSC Aging Candidate Genes

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

CXCR4 Signaling in AML Is Dampened By the Endogenous CXCR4 Inhibitory Peptide EPI-X4

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only